[Pharmacokinetically guided dose-escalation (PGDE) strategy].
When a phase I clinical trial is conducted, the dose escalation strategy is most critical. According to the results of preclinical trials, a rapid and safe dose escalation is necessary. In this regard, a pharmacokinetically guided dose-escalation (PGDE) strategy has been developed. An accelerated dose escalation is conducted by PGDE until reaching 40% target AUC. To determine the MTD of target anti-cancer agents, PGDE appears to be useful.